State Street’s Avalo Therapeutics AVTX Stock Holding History

State Street’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07M	Sell	71,654 -7,600	-10%	-$119K	﹤0.01%	3473
2025 Q4	$1.44M	Buy	79,254 +33,800	+74%	+$570K	﹤0.01%	3434
2025 Q3	$578K	Buy	+45,454	New	+$391K	﹤0.01%	3630
2023 Q4	–	Sell	-107	Closed	-$3.1K	–	4441
2023 Q3	$3.1K	Hold	107	–	–	﹤0.01%	4547
2023 Q2	$9.11K	Hold	107	–	–	﹤0.01%	4651
2023 Q1	$44.9K	Hold	107	–	–	﹤0.01%	4527
2022 Q4	$131K	Hold	107	–	–	﹤0.01%	4283
2022 Q3	$85K	Hold	107	–	–	﹤0.01%	4515
2022 Q2	$154K	Sell	107 -232	-68%	-$310K	﹤0.01%	4324
2022 Q1	$708K	Sell	339 -4	-1%	-$10K	﹤0.01%	3916
2021 Q4	$1.68M	Buy	343 +4	+1%	+$24K	﹤0.01%	3688
2021 Q3	$2.13M	Buy	339 +12	+4%	+$97.3K	﹤0.01%	3594
2021 Q2	$3.08M	Buy	327 +123	+60%	+$1.03M	﹤0.01%	3460
2021 Q1	$1.78M	Buy	204 +50	+32%	+$472K	﹤0.01%	3481
2020 Q4	$1.17M	Buy	154 +4	+3%	+$27.8K	﹤0.01%	3530
2020 Q3	$983K	Buy	150 +13	+9%	+$97.7K	﹤0.01%	3444
2020 Q2	$1.02M	Sell	137 -1	-0.7%	-$7.26K	﹤0.01%	3413
2020 Q1	$987K	Buy	138 +2	+1%	+$21.2K	﹤0.01%	3309
2019 Q4	$2.12M	Buy	136 +17	+14%	+$179K	﹤0.01%	3225
2019 Q3	$1.13M	Buy	119 +20	+20%	+$223K	﹤0.01%	3371
2019 Q2	$1.54M	Buy	+99	New	+$1.5M	﹤0.01%	3331

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street's AVTX Position: Q1 2026 in Review

State Street reduced its Avalo Therapeutics (AVTX) stake by 9.6% in Q1 2026, selling an estimated $119K and leaving 71,654 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3473.

State Street first reported a position in AVTX in Q2 2019 and has held it in 21 quarters since. The position peaked at $3.08M in Q2 2021. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

State Street held 71,654 shares of Avalo Therapeutics worth $1.07M as of Q1 2026.
State Street sold 7,600 Avalo Therapeutics shares in Q1 2026, an estimated $119K.
Avalo Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3473 holding.
State Street first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 21 quarters since.
State Street's Avalo Therapeutics position peaked at $3.08M in Q2 2021.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.